{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T13:53:56Z","timestamp":1648821236207},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T00:00:00Z","timestamp":1544659200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00277-018-3588-y","type":"journal-article","created":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T19:55:33Z","timestamp":1544730933000},"page":"1519-1520","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Successful retreatment with 3-week rituximab-bendamustine with high-dose dexamethasone in patients with relapsed\/refractory mantle cell lymphoma"],"prefix":"10.1007","volume":"98","author":[{"given":"Wolfgang","family":"Lamm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Kiesewetter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Puhr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner","family":"Dolak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marius E.","family":"Mayerh\u00f6fer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Raderer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,13]]},"reference":[{"key":"3588_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1470-2045(00)00255-2","volume":"2","author":"I Barista","year":"2001","unstructured":"Barista I, Romaguera JE, Cabanillas F (2001) Mantle-cell lymphoma. The Lancet Oncology 2:141\u2013148","journal-title":"The Lancet Oncology"},{"key":"3588_CR2","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1038\/sj.leu.2402272","volume":"15","author":"M Bernard","year":"2001","unstructured":"Bernard M, Gressin R, Lefrere F, Drenou B, Branger B, Caulet-Maugendre S, Tass P, Brousse N, Valensi F, Milpied N, Voilat L, Sadoun A, Ghandour C, Hunault M, Leloup R, Mannone L, Hermine O, Lamy T (2001) Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype. Leukemia 15:1785\u20131791","journal-title":"Leukemia"},{"key":"3588_CR3","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grunhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Durk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W (2013) Study group indolent L: Bendamustine plus rituximab versus chop plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381:1203\u20131210","journal-title":"Lancet"},{"key":"3588_CR4","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, Hertzberg M, Kwan YL, Simpson D, Craig M, Kolibaba K, Issa S, Clementi R, Hallman DM, Munteanu M, Chen L, Burke JM (2014) Randomized trial of bendamustine-rituximab or r-chop\/r-cvp in first-line treatment of indolent nhl or mcl: the bright study. Blood 123:2944\u20132952","journal-title":"Blood"},{"key":"3588_CR5","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s00277-015-2404-1","volume":"94","author":"M Becker","year":"2015","unstructured":"Becker M, Tschechne B, Reeb M, Schwinger U, Bruch HR, Frank M, Strassl L (2015) Bendamustine as first-line treatment in patients with advanced indolent non-hodgkin lymphoma and mantle cell lymphoma in german routine clinical practice. Ann Hematol 94:1553\u20131558","journal-title":"Ann Hematol"},{"key":"3588_CR6","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1007\/s12185-016-2146-4","volume":"105","author":"M Ogura","year":"2017","unstructured":"Ogura M, Ishizawa K, Maruyama D, Uike N, Ando K, Izutsu K, Terui Y, Imaizumi Y, Tsukasaki K, Suzuki K, Izumi T, Usuki K, Kinoshita T, Taniwaki M, Uoshima N, Suzumiya J, Kurosawa M, Nagai H, Uchida T, Fukuhara N, Choi I, Ohmachi K, Yamamoto G, Tobinai K (2017) Japanese Bendamustine Lymphoma Study G: bendamustine plus rituximab for previously untreated patients with indolent b-cell non-hodgkin lymphoma or mantle cell lymphoma: a multicenter phase ii clinical trial in Japan. Int J Hematol 105:470\u2013477","journal-title":"Int J Hematol"},{"key":"3588_CR7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(15)00447-7","volume":"17","author":"M Rummel","year":"2016","unstructured":"Rummel M, Kaiser U, Balser C, Stauch M, Brugger W, Welslau M, Niederle N, Losem C, Boeck HP, Weidmann E, von Gruenhagen U, Mueller L, Sandherr M, Hahn L, Vereshchagina J, Kauff F, Blau W, Hinke A, Barth J (2016) Study Group Indolent L: Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. The Lancet Oncology 17:57\u201366","journal-title":"The Lancet Oncology"},{"key":"3588_CR8","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1007\/s00277-015-2478-9","volume":"94","author":"MS Czuczman","year":"2015","unstructured":"Czuczman MS, Goy A, Lamonica D, Graf DA, Munteanu MC, van der Jagt RH (2015) Phase ii study of bendamustine combined with rituximab in relapsed\/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings. Ann Hematol 94:2025\u20132032","journal-title":"Ann Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3588-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-018-3588-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3588-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T00:08:16Z","timestamp":1576195696000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-018-3588-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,13]]},"references-count":8,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["3588"],"URL":"https:\/\/doi.org\/10.1007\/s00277-018-3588-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,13]]},"assertion":[{"value":"21 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors gave their informed consent for this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}